Brief: Bcal Diagnostics Posts HY Net Loss Attributable A$4 Mln
28/02/2025 01:32
Feb 28 (Reuters) - BCAL Diagnostics Ltd BDX.AX: HY NET LOSS ATTRIBUTABLE A$4 MILLION Further company coverage: BDX.AX ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on BCAL Diagnostics
See all newsAustralia's Genetic Signatures urges largest stakeholder to clarify merger intentions; shares rise
Brief: BCAL Diagnostics Introduces Avantect Multi-Cancer Early Detection Test
Brief: BCAL Diagnostics Clarifies Of Bcal's Position In Relation To Genetic Signatures
Brief: Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
Brief: BCAL To Acquire Shares In Genetic Signatures